Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious and inflammatory mediated diseases. The Immuron news feed on Stock Titan aggregates company announcements, market updates and regulatory disclosures so readers can follow developments around its commercial products and clinical pipeline.
News about Immuron frequently highlights Travelan®, an over‑the‑counter immune supplement and dietary supplement based on hyper‑immune bovine antibodies that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Company updates have reported record Travelan sales in Australia and North America, marketing initiatives in retail and online channels, and clinical trial activity involving IMM‑124E, the active ingredient in Travelan, in collaboration with the Uniformed Services University.
Investors and followers can also expect coverage of pipeline milestones such as FDA interactions and clinical plans for IMM‑529, a candidate for Clostridioides difficile infection, and IMM‑986, a pre‑clinical program targeting vancomycin‑resistant enterococci. Immuron’s announcements describe pre‑clinical results, Investigational New Drug submissions and approvals, and collaborations with institutions including Naval Medical Research Command, Walter Reed Army Institute of Research and Monash University.
In addition, the news stream includes letters to shareholders, sales updates, distribution agreements such as the ProIBS® IBS product in Australia and New Zealand, and corporate communications about investor engagement initiatives. Bookmark this page to access a consolidated view of Immuron’s operational, clinical, commercial and corporate news as it is released through official channels.
Immuron (Nasdaq:IMRN) reported first-half FY2026 results and a strategic update. Global product revenue was AUD $4.18 million, up ~5% year-over-year, with Australian revenue +13% and U.S. revenue +17%. Gross margin was 63.4% and net loss narrowed to AUD $(1.92) million.
The company raised ~AUD $7.3 million via an at-the-market facility, bringing cash to ~AUD $10.0 million and providing runway into 2027. FDA authorization was granted to proceed with a randomized Phase 2 trial for IMM-529; ProIBS® launched in Australia in December 2025.
Immuron (NASDAQ: IMRN) CEO Steven Lydeamore will present virtually at the Coffee Microcaps Conference on 5 March 2026 from 11:00–11:30am Australian Eastern Time. A slide deck is available on the company investor website and the presentation is scheduled as a 30-minute virtual session.
Immuron (NASDAQ: IMRN) reported H1 FY26 results and a strategic reset on Feb 25, 2026. Global H1 FY26 sales rose to AUD $4.2 million with U.S. sales up 17% YoY. Cash on hand is AUD $10.0 million, including AUD $7.3 million net raised at A$0.0803 average price. The company highlighted its Hyper-Immune platform, progress toward an end-of-Phase-2 meeting for IMM-124E, and FDA IND approval for IMM-529. Management said it will pursue partnerships to fund Travelan (IMM-124E) and IMM-529 clinical programs.
Immuron (Nasdaq:IMRN) reported first-half fiscal 2026 revenue of AUD$4.2 million for the six months ended December 31, 2025, a 5% increase year-over-year driven by Travelan sales in Australia and the U.S. Australian revenue rose 13% to AUD$3.3 million and U.S. revenue rose 17% to AUD$0.9 million; Canadian revenue declined due to distributor inventory dynamics.
The firm launched ProIBS in December 2025 in Australia and continues to invest in its polyclonal antibody platform and clinical-stage pipeline. Emerging Growth Research maintained a Buy-Extended rating and a $3.50 12-month price target, citing current product revenue, early commercial traction, and clinical potential while noting reliance on external capital to fund development.
Immuron (NASDAQ: IMRN) reported continued unaudited sales growth for Travelan® in H1 FY26 with global H1 sales of AUD$4.2 million, up 5% on the prior comparative period. Key regional results included Australia H1 AUD$3.3 million, +13%; USA H1 AUD$0.9 million, +17%; and Canada H1 AUD$56 thousand, -85% while Canada Q2 recovered +191% quarter-on-quarter. Growth in Australia and the U.S. was attributed to expanded digital/social marketing, promotions, new store listings and increased travel; a one-off reduction in stock holdings from the merged Sigma Healthcare/Chemist Warehouse group offset some Australian gains. ProIBS® launched in Australia before Christmas and is listed with two of three major pharmacy wholesalers and five banner groups.
Immuron (NASDAQ: IMRN) announced a U.S. Department of Defense-funded research award to develop two oral therapeutics targeting Campylobacter jejuni and Shigella sonnei.
Under a collaboration with military research institutes and the Henry M. Jackson Foundation, new vaccine preparations were formulated and provided to Immuron, which will produce two hyper-immune bovine colostrum products for pre-clinical evaluation aimed at a combined colostrum-based therapeutic for U.S. military use.
The company said topline results from the Uniformed Services University P2TD clinical trial (NCT04605783) of IMM-124E (Travelan active ingredient) are expected to be announced at the end of next week.
Immuron (NASDAQ:IMRN) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for IMM-529 (IND 032095), enabling a Phase 2 randomized, double-blind, placebo-controlled trial in CDI patients to proceed.
The study will enroll up to 60 subjects in a 2:1 IMM-529+SOC versus placebo+SOC design across multiple Australian sites, with first-half 2026 start planned. Primary objectives are safety and tolerability; efficacy will be measured by mortality, symptom scores and recurrence.
Immuron cites preclinical results (prevention 80%; recurrence protection 67%; treatment 78.6%) and projects a base-case yearly revenue of US$400M if positioned at first recurrence, noting anticipated payer restrictions and oral dosing as a favorable attribute.
Immuron (NASDAQ: IMRN) provided a clinical update on IMM-529 and Travelan on Oct 31, 2025. The company said its IMM-529 IND for Clostridioides difficile has been acknowledged by FDA CBER with an assigned biologic name and IND number, and is under active review after an Oct 25, 2025 FDA request for additional clinical information. Immuron submitted a comprehensive reply and made minor protocol updates ahead of the 30-day decision date.
The Uniformed Services University Travelan P2TD study (n=851) topline results were delayed from end-Oct to end-Nov 2025 due to a U.S. government shutdown; those results will inform End-of-Phase 2 dosing (twice-daily vs three-times-daily).
Immuron (NASDAQ: IMRN) reported unaudited Q1 FY26 sales of AUD$2.0 million, up 34% year-over-year. Regional results show Australia AUD$1.6M (+52% YoY), USA AUD$0.4M (+44% YoY) and Canada AUD$0.0M (down 92% YoY).
Management attributes growth to increased digital and social media marketing, same-store promotion effects, new retail listings in FY25 and higher South East Asian travel; U.S. growth was supported by an improved Amazon store, local social channels and paid/influencer campaigns. Canada had a large FY25 pipeline fill into over 1,000 retail doors and sales are expected to recover with seasonal travel and promotional activity later in the calendar year.
Immuron (NASDAQ: IMRN) submitted an IND to the FDA for clinical development of IMM-529 to treat Clostridioides difficile infection (CDI) and prevent recurrent CDI (rCDI). The company plans to initiate a Phase 2 trial in H1 2026 enrolling first-episode and recurrent CDI patients. An independent market analysis estimates an eligible population of ~98,000 patients at first recurrence and a base-case annual revenue potential of ~US$400M pending efficacy. IMM-529 is an oral, three-target polyclonal antibody candidate directed at Toxin B, spores, and surface layer proteins, with preclinical results reporting prevention of primary disease (80% P=0.0052), protection of recurrence (67% P<0.01) and treatment of primary disease (78.6% P<0.0001).